NewAmsterdam Pharma Company NV
NAMS
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.3B
Close$
$3.08
84.4% downside
Current Fair Value
84.4% downsideOvervalued by 84.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.30 Billion |
|---|---|
| Enterprise Value | $1.88 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.75 |
| Beta | 0.1 |
| Outstanding Shares | 123,370,232 |
Return
| Return on Equity | -41.10% |
|---|---|
| Return on Assets | -36.84% |
| Return on Invested Capital | -40.57% |
Valuation & Multiples
| P/E Ratio | -9.04 |
|---|---|
| PEG | -3.36 |
| Price to Sales | - |
| Price to Book Ratio | 3.94 |
| Enterprise Value to Revenue | 264.42 |
| Enterprise Value to EBIT | -7.35 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-0.48
Average shareholder expectationRevenue Estimate
$1.88 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.49
Average shareholder expectationRevenue Estimate
$7.54 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 6.9406▲ 509.80% |
|---|---|
| Total Calls | 306,300▲ 4.61% |
| Total Puts | 2,125,900▲ 294.05% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 98.88%▼ 3.22% |
|---|---|
| Total Invested | $4.13B▲ 4.29% |
| Investors Holding | 213▲ 31.00% |
ESG Score
No data